November 7, 2016
Pfizer Inc. has announced that it will present 20 abstracts for XELJANZ® (tofacitinib citrate) at the upcoming 2016 ACR/ARHP Annual Meeting (November 11-16, Washington, DC). More importantly, for the first time, results from the two pivotal Phase 3 OPAL (Oral Psoriatic Arthritis TriaL) studies of tofacitinib – the only Janus kinase (JAK) inhibitor under investigation for psoriatic arthritis (PsA) – will be presented. OPAL Beyond will be presented during a late-breaking abstract poster session, and OPAL Broaden will be highlighted during a plenary session. Furthermore, new and updated research for XELJANZ in rheumatoid arthritis (RA) will be presented.
Michael Corbo, Chief Development Officer, Inflammation & Immunology, Pfizer Global Product Development, said: “As part of our commitment to inflammation and immunology, we continue to advance our leading science in the research of Janus kinase inhibition. The extensive data being presented at this year’s ACR/AHRP annual meeting expands upon our knowledge about the role of XELJANZ for the treatment of moderate to severe rheumatoid arthritis and also highlights its potential, if approved, for the treatment of psoriatic arthritis.”